A5058128517- Heart Failure Treatment and Management
- Cardiovascular Function and Risk Factors
- Venous Thromboembolism Diagnosis and Management
- Heparin-Induced Thrombocytopenia and Thrombosis
- Sarcoidosis and Beryllium Toxicity Research
- Neuroendocrine Tumor Research Advances
- Atrial Fibrillation Management and Outcomes
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Cardiac pacing and defibrillation studies
- Electrolyte and hormonal disorders
- Potassium and Related Disorders
- Cardiac Structural Anomalies and Repair
- Cardiac electrophysiology and arrhythmias
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Acute Myocardial Infarction Research
- Vasculitis and related conditions
- Intramuscular injections and effects
- Platelet Disorders and Treatments
- Viral Infections and Immunology Research
- Childhood Cancer Survivors' Quality of Life
- Cardiac Arrhythmias and Treatments
- Antiplatelet Therapy and Cardiovascular Diseases
- Parathyroid Disorders and Treatments
- Pneumocystis jirovecii pneumonia detection and treatment
- Mechanical Circulatory Support Devices
Johns Hopkins Hospital
2017-2023
Johns Hopkins University
2016-2020
Johns Hopkins Medicine
2017-2020
This study sought to determine the efficacy and safety of a novel, pH-neutral formulation furosemide administered subcutaneously (SC) for treatment acute decompensated heart failure (HF). Congestion requiring intravenous (IV) administration diuretic agent is main reason patients with HF present medical care. Outpatients presenting were randomized receive single SC or IV dose furosemide. Primary outcome was 6-h urine output, secondary outcomes weight change, natriuresis, adverse events....
Background Heart failure with preserved ejection fraction ( HF p EF ) constitutes half of hospitalized heart cases and is commonly associated obesity. The role natriuretic peptide levels in obese patients , however, not well defined. We sought to evaluate change NT ‐pro BNP (N‐terminal pro‐B‐type peptide) by obesity category related clinical outcomes for acute failure. Methods Results A total 89 decompensated were stratified into 3 categories: nonobese body mass index [BMI] <30.0 kg/m 2...
Background: An antithrombotic stewardship program was implemented to reduce IV DTI use and increase fondaparinux direct oral anticoagulant (DOAC) for suspected or confirmed Heparin-induced thrombocytopenia (HIT). Objectives: This study evaluated the impact of an on utilization in patients with HIT. Methods: A retrospective analysis adults receiving DTIs from July 2016 2017 (pre-stewardship) October 2019 (post-stewardship) conducted. Results: The median duration administration not...
Introduction: Utilizing beta blockers to lower cardiac output and improve oxygenation is safe effective during venovenous (VV) extracorporeal membrane (ECMO) support; however, ivabradine has never been studied in this setting. The purpose of study determine safety, efficacy, optimal dosing patients receiving VV ECMO. Methods: This was a single-center, retrospective cohort conducted at tertiary academic hospital from January 1, 2020 July 2022. Patients were included if they 18 years or older...
IntroductionHeart failure with preserved ejection fraction (HFpEF) constitutes half of all HF hospitalizations. Atrial fibrillation (AF) is a common co-morbid condition in HFpEF and an independent predictor mortality patients HFpEF. The effect AF on hospitalized HFpEF, however, has not been well described. Here, we report the response to acute treatment 30-day hospital readmissions cohort.MethodsSubjects enrolled Randomized Evaluation Heart Failure With Preserved Ejection Fraction Patients...